AI assistant
GlaxoSmithKline PLC — Remuneration Information 2019
May 13, 2019
5262_rns_2019-05-13_2c1a17a8-40b4-438e-90ee-7c52dda1527e.html
Remuneration Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 8829Y
GlaxoSmithKline PLC
13 May 2019
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date: 13 May 2019
| Name of applicant: | GlaxoSmithKline plc | |||
| Name of scheme: | GlaxoSmithKline plc 2009 Deferred Annual Bonus Plan | |||
| Period of return: | From: | 1 November 2018 | To: | 30 April 2019 |
| Balance of unallotted securities under scheme(s) from previous return: | 547,331 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 393,607 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 153,724 | |||
| Name of contact: | Victoria Whyte |
| Telephone number of contact: | 020 8047 5000 |
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date: 13 May 2019
| Name of applicant: | GlaxoSmithKline plc | |||
| Name of scheme: | GlaxoSmithKline Share Option Plan - Ordinary Shares | |||
| Period of return: | From: | 1 November 2018 | To: | 30 April 2019 |
| Balance of unallotted securities under scheme(s) from previous return: | 2,223,352 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 958,344 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 1,265,008 | |||
| Name of contact: | Victoria Whyte |
| Telephone number of contact: | 020 8047 5000 |
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date: 13 May 2019
| Name of applicant: | GlaxoSmithKline plc | |||
| Name of scheme: | GlaxoSmithKline Share Option Plan - ADS | |||
| Period of return: | From: | 1 November 2018 | To: | 30 April 2019 |
| Balance of unallotted securities under scheme(s) from previous return: | 7,336,096 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 1,424,800 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 5,911,296 | |||
| Name of contact: | Victoria Whyte |
| Telephone number of contact: | 020 8047 5000 |
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date: 13 May 2019
| Name of applicant: | GlaxoSmithKline plc | |||
| Name of scheme: | GlaxoSmithKline plc Share Save Plan 2012 | |||
| Period of return: | From: | 1 November 2018 | To: | 30 April 2019 |
| Balance of unallotted securities under scheme(s) from previous return: | 5,672,623 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 3,345,727 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 2,326,896 | |||
| Name of contact: | Victoria Whyte |
| Telephone number of contact: | 020 8047 5000 |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
BLRDMGMKVFMGLZM